Drug products: Eucreas®, Galvus®
ATC code: A10BD08, A10BH02
The effect of vildagliptin on the enzyme dipeptidyl-peptidase-4 (DDP-4) is similar in men and women.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
In an open, parallel-group, clinical study, young and elderly healthy volunteers (20 men, 20 women) received a single dose of 100 mg vildagliptin. No clinically relevant differences in pharmacokinetic parameters were observed between men and women [1-3]. No dose adjustment based on sex is necessary .
Vildagliptin inhibits the enzyme dipeptidyl-peptidase-4 (DDP-4), which increases endogenous levels of incretin hormones, resulting in improved glucose-dependent insulin secretion. Inhibition of DDP-4 by vildagliptin is not affected by sex [1, 2]. No clinically relevant outcome studies have been found.
A large meta-analysis (7458 men, 6112 women) reported that vildagliptin was not associated with an increased risk of cardiovascular or cerebrovascular events, neither in men nor in women, relative to comparative drugs .
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2014-08-28
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson